JP2014509622A5 - - Google Patents

Download PDF

Info

Publication number
JP2014509622A5
JP2014509622A5 JP2014501569A JP2014501569A JP2014509622A5 JP 2014509622 A5 JP2014509622 A5 JP 2014509622A5 JP 2014501569 A JP2014501569 A JP 2014501569A JP 2014501569 A JP2014501569 A JP 2014501569A JP 2014509622 A5 JP2014509622 A5 JP 2014509622A5
Authority
JP
Japan
Prior art keywords
benzoate
amino
methyl
oxidepyridin
butanoate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014501569A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014509622A (ja
JP5959617B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/055364 external-priority patent/WO2012130821A1/en
Publication of JP2014509622A publication Critical patent/JP2014509622A/ja
Publication of JP2014509622A5 publication Critical patent/JP2014509622A5/ja
Application granted granted Critical
Publication of JP5959617B2 publication Critical patent/JP5959617B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014501569A 2011-03-29 2012-03-27 オタミキサバンの安息香酸塩 Active JP5959617B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11305348 2011-03-29
EP11305348.2 2011-03-29
US201161500342P 2011-06-23 2011-06-23
US61/500,342 2011-06-23
PCT/EP2012/055364 WO2012130821A1 (en) 2011-03-29 2012-03-27 Benzoic acid salt of otamixaban

Publications (3)

Publication Number Publication Date
JP2014509622A JP2014509622A (ja) 2014-04-21
JP2014509622A5 true JP2014509622A5 (enExample) 2015-03-19
JP5959617B2 JP5959617B2 (ja) 2016-08-02

Family

ID=44065390

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014501569A Active JP5959617B2 (ja) 2011-03-29 2012-03-27 オタミキサバンの安息香酸塩

Country Status (21)

Country Link
US (1) US8993602B2 (enExample)
EP (1) EP2691371B1 (enExample)
JP (1) JP5959617B2 (enExample)
KR (1) KR101852226B1 (enExample)
CN (1) CN103562183B (enExample)
AU (1) AU2012234325B2 (enExample)
BR (1) BR112013025105A2 (enExample)
CA (1) CA2830965C (enExample)
CY (1) CY1116659T1 (enExample)
DK (1) DK2691371T3 (enExample)
ES (1) ES2539236T3 (enExample)
HR (1) HRP20150613T1 (enExample)
IL (1) IL228574A (enExample)
MX (1) MX2013011266A (enExample)
MY (1) MY161396A (enExample)
PL (1) PL2691371T3 (enExample)
PT (1) PT2691371E (enExample)
RU (1) RU2597423C2 (enExample)
SG (1) SG193612A1 (enExample)
SI (1) SI2691371T1 (enExample)
WO (1) WO2012130821A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012234323A1 (en) 2011-03-29 2013-10-17 Sanofi Otamixaban formulations with improved stability
CN106565698B (zh) * 2016-08-15 2019-03-08 南京帕隆材料科技有限公司 取代噻唑类衍生物及其制备方法和用途
CN106518859B (zh) * 2016-08-15 2019-01-18 南京帕隆材料科技有限公司 噻唑类衍生物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424334A (en) 1991-12-19 1995-06-13 G. D. Searle & Co. Peptide mimetic compounds useful as platelet aggregation inhibitors
IL125163A0 (en) * 1996-01-02 1999-01-26 Rhone Poulenc Rorer Pharma Substituted n-[(aminoiminomethyl or aminomethyl) phenyl] propyl amides
US6080767A (en) * 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
GB0108903D0 (en) 2000-10-05 2001-05-30 Aventis Pharm Prod Inc Novel crystalline forms of a factor Xa inhibitor
EA020045B1 (ru) * 2007-05-02 2014-08-29 Портола Фармасьютиклз, Инк. Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
AU2010277725B2 (en) * 2009-07-29 2016-08-18 Sanofi Otamixaban for treatment of elderly and renal impaired non-ST elevation myocardial infarction patients

Similar Documents

Publication Publication Date Title
JP2014515013A5 (enExample)
JP2012512885A5 (enExample)
HRP20210928T1 (hr) Soli ili ko-kristali 3- (3-dimetilamino-1-etil-2-metil-propil)-fenola
FI3102208T4 (fi) 2-hydroksi-6-((2-(1-isopropyyli-1h-pyratsol-5-yyli)pyridin-3-yyli)metoksi)bentsaldehydin vapaan emäksen kiteinen polymorfi
JP2017537066A5 (enExample)
JP2015508749A5 (enExample)
JP2014532638A5 (enExample)
JP2012507535A5 (enExample)
JP2015520769A5 (enExample)
CA2726005A1 (en) Process for the preparation of halogenated benzoic acid derivatives
ME02307B (me) Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol- 3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr
IN2014DN11207A (enExample)
JP2012176975A5 (enExample)
JP2020510661A5 (enExample)
JP2016522857A5 (enExample)
JP2014509622A5 (enExample)
JP2013532687A5 (enExample)
CN115315423A (zh) 取代芳基类化合物
JP2016532632A5 (enExample)
CR20140462A (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil} amino) -1-hidroxietil]-8-hidroquinolin-2(1h)-ona
SG179031A1 (en) Hsl inhibitors useful in the treatment of diabetes
JP2012051888A5 (enExample)
CN111936467A (zh) 作为c-Met激酶抑制剂的化合物的结晶及其制备方法和用途
NZ590315A (en) Fxa inhibitors with cyclic amidoxime or cyclic amidrazone as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof
JP2016516691A5 (enExample)